

**Summary statistics - quantitative results**

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

**EQA round: TE1/20 - Trace Elements**

Deadline: 20.04.2020

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability											
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>						
<b>Set 1 (plasma)</b>																		
<b>(361) Al - plasma</b>																		
Samples and groups		[µmol/L]						1				1 1 100%						
Sample A1		0,630						1	CVE	0,56 0,089	25%	0,42 0,7						
Other								1	0			1						
Sample B1		1,57						1	CVE	1,45 0,16	25%	1,08 1,82						
Other								1	0			1						
1x 2																		
<b>(357) Cr - plasma</b>																		
Samples and groups		[nmol/L]						1				1 1 100%						
Sample A1		56,9						1	CVE	55,8 5,8	25%	41,8 69,8						
Other								1	0			1						
Sample B1		232						1	CVE	227 17	25%	170 284						
Other								1	0			1						
1x 2																		
<b>(351) Cu - plasma</b>																		
Samples and groups		[µmol/L]						19				19 17 89%						
Sample A1		11,7 1,7 14						19	CVE	12,5 0,65	25%	9,37 15,7						
(2) ET-AAS		12,0 0,52 4,3						5	0									
(5) Spectrophotometry		11,8 2,0 17						10	0									
Other								4	0			4						
Sample B1		21,5 2,3 11						19	CVE	22,9 1,0	25%	17,1 28,7						
(2) ET-AAS		22,2 1,6 7,3						5	0									
(5) Spectrophotometry		20,5 2,9 14						10	0									
Other								4	0			4						
4x 1																		
<b>(352) Mn - plasma</b>																		
Samples and groups		[nmol/L]						2				2 1 50%						
Sample A1		122 42 34						2	CVE	85,5 9,1	25%	64,1 107						
Other								2	0			2						
2x 2																		
Sample B1		292 45 15						2	CVE	264 18	25%	198 330						
Other								2	0			2						
2x 2																		
<b>(355) Se - plasma</b>																		
Samples and groups		[µmol/L]						6				6 6 100%						
Sample A1		0,795 0,096 12						6	CVE	0,854 0,040	25%	0,64 1,07						
(2) ET-AAS		0,795 0,096 12						5	0									
Other								1	0			1						
1x 4																		
Sample B1		2,14 0,16 7,3						6	CVE	2,07 0,094	25%	1,55 2,59						
(2) ET-AAS		2,17 0,11 5,1						5	0									
Other								1	0			1						
1x 4																		
<b>(350) Zn - plasma</b>																		
Samples and groups		[µmol/L]						18				18 18 100%						
Sample A1		28,2 2,2 7,9						18	CVE	28,8 1,2	25%	21,6 36						
(1) F-AAS		28,6 2,1 7,3						9	0									
(5) Spectrophotometry		27,6 1,8 6,7						9	0									
Sample B1		41,8 3,1 7,5						18	CVE	43,2 1,6	25%	32,4 54						
(1) F-AAS		42,4 4,1 9,7						9	0									
(5) Spectrophotometry		40,9 2,9 7,1						9	0									
1x 4																		
<b>Set 2 (blood)</b>																		
<b>(353) Cd - blood</b>		[nmol/L]						1				1 1 100%						
Samples and groups		19,9						1	CVE	19,6 0,89	25%	14,7 24,5						
Sample A2								1	0			1						
Other								1x 2										
Sample B2		38,9						1	CVE	45,4 2,7	25%	34 56,8						
Other								1	0			1						
1x 2																		

**Summary statistics - quantitative results**

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

**EQA round: TE1/20 - Trace Elements**

Deadline: 20.04.2020

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability						N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(356) Hg - blood</b>	[nmol/L]				1								1	1	100%
Samples and groups															
<b>Sample A2</b>		14,6			1	CVE	14	1,5	25%	10,5	17,5		1	1	100%
Other					1	0									1
<b>Sample B2</b>		55,2			1	CVE	51,8	5,0	25%	38,8	64,8		1	1	100%
Other					1	0									1
<b>(354) Pb - blood</b>	[nmol/L]				4								4	4	100%
Samples and groups															
<b>Sample A2</b>		336	31	9,3	4	CVE	348	17	25%	261	435		4	4	100%
Other					4	0									4
<b>Sample B2</b>		1100	33	3,0	4	CVE	1130	46	25%	847	1420		4	4	100%
Other					4	0									4

st\_kn\_p

End of report

Printed: 28.04.2020